At Aquila, we can help you harness the power of Next Generation Sequencing-based technologies to characterise individual cells or pooled samples and generate a wealth of genomics and transcriptomics data to further your drug discovery pipeline.
We are expanding our RNA-sequencing service offering with the 10x Genomics® Chromium™ System. In addition to the NanoString platform, we will soon be able to offer single-cell and bulk RNA-seq as readouts to our in vitro, in vivo or ex vivo assay systems. We will work closely with you to help you gain more insights into the mechanism of action of your compounds, understanding what cell types are affected and what signalling pathways or downstream genes are regulated.
Not sure whether NGS or NanoString is best for your program? Talk to us today about your discovery pipeline so we can support your best route to clinic.